David James Lennon Sells 5,690 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) CEO David James Lennon sold 5,690 shares of Aadi Bioscience stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $2.35, for a total transaction of $13,371.50. Following the completion of the sale, the chief executive officer now owns 33,429 shares in the company, valued at $78,558.15. This trade represents a 14.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aadi Bioscience Trading Up 0.4 %

Shares of AADI stock opened at $2.31 on Wednesday. Aadi Bioscience, Inc. has a 1 year low of $1.21 and a 1 year high of $3.81. The firm’s fifty day moving average price is $2.93 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $57.05 million, a P/E ratio of -1.01 and a beta of 0.64.

Institutional Trading of Aadi Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BML Capital Management LLC acquired a new position in Aadi Bioscience during the third quarter valued at approximately $4,120,000. Peapod Lane Capital LLC acquired a new stake in shares of Aadi Bioscience in the 4th quarter valued at approximately $1,397,000. XTX Topco Ltd bought a new position in shares of Aadi Bioscience in the third quarter valued at $32,000. Two Sigma Investments LP grew its stake in shares of Aadi Bioscience by 305.2% in the fourth quarter. Two Sigma Investments LP now owns 68,555 shares of the company’s stock valued at $216,000 after buying an additional 51,638 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Aadi Bioscience by 95.2% during the fourth quarter. Two Sigma Advisers LP now owns 61,686 shares of the company’s stock worth $195,000 after buying an additional 30,086 shares during the last quarter. Institutional investors and hedge funds own 52.08% of the company’s stock.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.